Desai, J., Frentzas, S., Fakih, M., Ameratunga, M., O'Neill, S., Pelster, M., Stein, B. N., Body, A., Li, B., Strauss, R. M., Zhao, Y., Dong, G., Cecchini, M. (2025). First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.123